Maeda K - Search Results

1

Comparison of Rapid Antigen Tests for COVID-19.

Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Yamayoshi S, et al. Among authors: maeda k. Viruses. 2020 Dec 10;12(12):1420. doi: 10.3390/v12121420. Viruses. 2020. PMID: 33322035 Free PMC article.

2

Identification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replication.

Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H. Miyakawa T, et al. Among authors: maeda k. J Biol Chem. 2002 Feb 15;277(7):4649-55. doi: 10.1074/jbc.M109198200. Epub 2001 Dec 4. J Biol Chem. 2002. PMID: 11734558 Free article.

3

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.

Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T, Mitsuya H. Maeda K, et al. Curr Opin Pharmacol. 2004 Oct;4(5):447-52. doi: 10.1016/j.coph.2004.07.004. Curr Opin Pharmacol. 2004. PMID: 15351348 Review.

4

Development of therapeutics for AIDS: structure-based molecular targeting.

Maeda K, Mitsuya H. Maeda K, et al. Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S31-4. doi: 10.1016/j.tube.2007.05.009. Epub 2007 Jul 10. Tuberculosis (Edinb). 2007. PMID: 17625972 Review.

5

[Structure-guided molecular-targeting approach for development of AIDS therapeutics].

Maeda K, Mitsuya H. Maeda K, et al. Nihon Rinsho. 2010 Oct;68(10):1889-95. Nihon Rinsho. 2010. PMID: 20954335 Review. Japanese.

6

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.

Yasutake Y, Hattori SI, Hayashi H, Matsuda K, Tamura N, Kohgo S, Maeda K, Mitsuya H. Yasutake Y, et al. Among authors: maeda k. Sci Rep. 2018 Jan 26;8(1):1624. doi: 10.1038/s41598-018-19602-9. Sci Rep. 2018. PMID: 29374261 Free PMC article.

7

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro.

Hattori SI, Matsuda K, Tsuchiya K, Gatanaga H, Oka S, Yoshimura K, Mitsuya H, Maeda K. Hattori SI, et al. Among authors: maeda k. Front Microbiol. 2018 Sep 19;9:2022. doi: 10.3389/fmicb.2018.02022. eCollection 2018. Front Microbiol. 2018. PMID: 30283406 Free PMC article.

8

Matsuda K, Kobayakawa T, Tsuchiya K, Hattori SI, Nomura W, Gatanaga H, Yoshimura K, Oka S, Endo Y, Tamamura H, Mitsuya H, Maeda K. Matsuda K, et al. Among authors: maeda k. J Biol Chem. 2019 Jan 4;294(1):116-129. doi: 10.1074/jbc.RA118.005798. Epub 2018 Nov 9. J Biol Chem. 2019. PMID: 30413535 Free PMC article.

9

Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors.

Yasutake Y, Hattori SI, Tamura N, Matsuda K, Kohgo S, Maeda K, Mitsuya H. Yasutake Y, et al. Among authors: maeda k. Biochem Biophys Res Commun. 2019 Feb 19;509(4):943-948. doi: 10.1016/j.bbrc.2019.01.026. Epub 2019 Jan 14. Biochem Biophys Res Commun. 2019. PMID: 30648556

10

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.

Yasutake Y, Hattori SI, Tamura N, Matsuda K, Kohgo S, Maeda K, Mitsuya H. Yasutake Y, et al. Among authors: maeda k. Sci Rep. 2020 Feb 20;10(1):3021. doi: 10.1038/s41598-020-59775-w. Sci Rep. 2020. PMID: 32080249 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,816 results

Search Page